Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Atherosclerosis III: Management01:26

Atherosclerosis III: Management

529
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
529
Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

776
Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
776
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

431
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
431
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

551
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
551
Exercise and Cardiovascular Response01:20

Exercise and Cardiovascular Response

4.7K
Exercise significantly impacts cardiovascular response, which is crucial for understanding patient health and designing effective treatment plans.
Light to moderate physical activity initiates a series of interconnected responses in the body. The heart rate modestly increases in anticipation of the workout, followed by widespread vasodilation as oxygen consumption by skeletal muscles increases. This results in decreased peripheral resistance, increased capillary blood flow, and accelerated...
4.7K
Peripheral Artery Disease III: Interprofessional Care01:27

Peripheral Artery Disease III: Interprofessional Care

446
Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
446

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Hypertension in all situations].

MMW Fortschritte der Medizin·2022
Same author

[Dyspnoea - the view of the cardiologist].

MMW Fortschritte der Medizin·2019
Same author

European Patent in Immunoncology: From Immunological Principles of Implantation to Cancer Treatment.

International journal of molecular sciences·2019
Same author

[Modern stepped care treatment of arterial hypertension].

MMW Fortschritte der Medizin·2018
Same author

MMW Fortschritte der Medizin·2017
Same author

[Blood Pressure Measurement and Treatment Targets: Position Paper of the DHL® Task Force Scientific Statements and Guidelines].

Deutsche medizinische Wochenschrift (1946)·2017

Related Experiment Video

Updated: Mar 3, 2026

A Novel Digital Platform for a Monitored Home-based Cardiac Rehabilitation Program
04:24

A Novel Digital Platform for a Monitored Home-based Cardiac Rehabilitation Program

Published on: April 19, 2019

12.7K

Reducing Cardiovascular Morbidity and Mortality in the Elderly.

Peter Trenkwalder1

  • 1a Department of Medicine, University of Munich, Starnberg Hospital, Starnberg, Germany.

Blood Pressure
|April 21, 2017
PubMed
Summary

The SCOPE trial investigated candesartan cilexetil for mild hypertension in elderly patients. This study assessed its impact on cardiovascular events and cognitive decline, offering insights into treating this common condition.

Area of Science:

  • Cardiology
  • Geriatrics
  • Pharmacology

Background:

  • Elderly patients with mild hypertension are a vulnerable group with high risks of cardiovascular and cerebrovascular events, including dementia.
  • Previous studies focused on moderate hypertension, leaving a gap in understanding treatment benefits for mild cases in the elderly.
  • Effective blood pressure control is crucial for reducing morbidity and mortality in older adults.

Purpose of the Study:

  • To evaluate the efficacy of candesartan cilexetil in reducing major cardiovascular events in elderly patients with mild hypertension.
  • To determine the effect of candesartan cilexetil on preventing cognitive impairment in this population.
  • To assess the cardiovascular and cerebrovascular protective benefits of angiotensin II type 1 receptor blockers in the elderly.

Main Methods:

More Related Videos

Author Spotlight: Exercise Test for Evaluation of the Functional Efficacy of the Pig Cardiovascular System
02:47

Author Spotlight: Exercise Test for Evaluation of the Functional Efficacy of the Pig Cardiovascular System

Published on: May 12, 2023

2.1K
Hydra, a Computer-Based Platform for Aiding Clinicians in Cardiovascular Analysis and Diagnosis
07:51

Hydra, a Computer-Based Platform for Aiding Clinicians in Cardiovascular Analysis and Diagnosis

Published on: September 26, 2018

8.1K

Related Experiment Videos

Last Updated: Mar 3, 2026

A Novel Digital Platform for a Monitored Home-based Cardiac Rehabilitation Program
04:24

A Novel Digital Platform for a Monitored Home-based Cardiac Rehabilitation Program

Published on: April 19, 2019

12.7K
Author Spotlight: Exercise Test for Evaluation of the Functional Efficacy of the Pig Cardiovascular System
02:47

Author Spotlight: Exercise Test for Evaluation of the Functional Efficacy of the Pig Cardiovascular System

Published on: May 12, 2023

2.1K
Hydra, a Computer-Based Platform for Aiding Clinicians in Cardiovascular Analysis and Diagnosis
07:51

Hydra, a Computer-Based Platform for Aiding Clinicians in Cardiovascular Analysis and Diagnosis

Published on: September 26, 2018

8.1K
  • A prospective, randomized, double-blind, parallel-group trial involving approximately 5000 elderly patients (70-89 years) with mild hypertension.
  • Patients received either candesartan cilexetil (8 or 16 mg daily) or a placebo for a mean follow-up period of 2.5 years.
  • Primary endpoint: major cardiovascular events (death, stroke, myocardial infarction). Secondary endpoint: cognitive impairment prevention.

Main Results:

  • Candesartan cilexetil demonstrated effectiveness in lowering blood pressure with placebo-like tolerability.
  • The study is designed to provide definitive evidence on cardiovascular and cerebrovascular benefits.
  • Angiotensin II type 1 receptor blockers may offer protection against target organ damage.

Conclusions:

  • Candesartan cilexetil is a well-tolerated antihypertensive medication for elderly patients with mild hypertension.
  • Treating mild hypertension in the elderly with candesartan cilexetil may reduce cardiovascular and cerebrovascular events.
  • This therapy shows potential for protecting against cognitive decline and target organ damage in older adults.